Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.39 |
| ▸ | CCR6 | P51684 | 1/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.36 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4562543 | 0.88 | GPR119 (0.43) | GPR119CCR6SMN1; SMN2 | |
| SCHEMBL4422350 | 0.87 | GPR119 (0.53) | GPR119 | |
| SCHEMBL4415731 | 0.85 | GPR119 (0.57) | GPR119SMN1; SMN2 | |
| SCHEMBL4422114 | 0.84 | GPR119 (0.46) | GPR119 | |
| SCHEMBL4415589 | 0.83 | GPR119 (0.41) | GPR119CCR6SPHK1SPHK2 | |
| SCHEMBL4425713 | 0.79 | GPR119 (0.51) | GPR119 | |
| SCHEMBL4422156 | 0.79 | GPR119 (0.51) | GPR119 | |
| SCHEMBL4411702 | 0.78 | GPR119 (0.51) | GPR119SPHK1SPHK2 | |
| SCHEMBL4427077 | 0.77 | GPR119 (0.50) | GPR119MCHR1 | |
| SCHEMBL4427193 | 0.76 | GPR119 (0.49) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885CCR6 1571/4885SPHK1 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.